drugset
drugset / Trial / NCT02568397

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

NCT02568397 ↗

Phase 1 Completed 60 enrolled AstraZeneca Eli Lilly and Company · collab
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to learn about the effect of lanabecestat on how the body absorbs and processes dabigatran etexilate and how dabigatran etexilate affects lanabecestat when they are taken together. This study will last about 28 days and participants will be asked to take an lanabecestat tablet daily for 19 days and a dabigatran etexilate tablet on 3 occasions. Screening is required within 30 days prior to the start of the study.

Timeline

Start
2015-10-31
Primary completion
2016-01-31
Completion
2016-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown — Oral
Subject Lanabecestat Small molecule — Oral

Indications

No indication recorded.